3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
4
Completed
4
Active not recruiting
4
Withdrawn
1
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
6
Thoracic
1
Head & Neck
1
Endocrine
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Interventions
telotristat ethyl
4
lutetium Lu 177 dotatate
4
3-Iodobenzylguanidine
3
vandetanib
2
pasireotide
2
gallium Ga 68 dotatate
2
Temozolomide
2
Octreotide
2
Biological Therapy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vatalanib
1
trametinib
1
pembrolizumab
1
lanreotide
1
fosbretabulin
1
farletuzumab
1
dabrafenib
1
combretastatin
1
ceritinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Tretinoin
1
Tranexamic Acid
1
Solutions
1
Saline Solution
1
Panitumumab
1
Paclitaxel
1
Microarray Analysis
1
Isotretinoin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
dabrafenib
×
Endocrine
×
Clear all
NCT04739566
2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2
Withdrawn